BEVERLY-C: An Observational Study of Avastin (Bevacizumab) in First-Line Treatment in Elderly Patients With Metastatic Colorectal Cancer

Hoffmann-La Roche3 enrolled

Overview

This observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in combination with fluoropyrimidine-based chemotherapy in elderly patients (\>/= 65 years of age) with newly diagnosed metastatic colorectal cancer. Patients will be followed until disease progression, death, withdrawal of consent, discontinuation of physician-patient relationship or study closure, whichever comes first.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Colorectal Cancer

Eligibility

Sex: ALLMin age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients, \>/= 65 years of age * Patients with newly diagnosed metastatic colorectal cancer starting first-line treatment with Avastin in combination with fluoropyrimidine-based chemotherapy according to the approved Hungarian Summary of Product Characteristics * Patients suitable for Avastin treatment as assessed by the treating physician Exclusion Criteria: * Any contraindications to Avastin treatment according to the Hungarian Summary of Product Characteristics

Locations (1)

Unnamed facility

Budapest, Hungary